Supplementary Table 4. Primers of M-BCR used in the included studies

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| No  | Article  | Description  | Sequence reported in study | Primer sequence compared to reference & inverse complement deoxyribonucleic acid (icDNA) of reverse primer (refer to Supplementary Figure 1(a) *BCR* NCBI Reference Sequence & Supplementary Figure 2a/b *ABL1* variant a/b NCBI Reference Sequence) |
| 1 | Biernaux C 1995[4] | cDNA synthesis | 5’-TGTGATATAGCCTAAGACCCGGAG-3’ | ABL1 | 5’-CTCCGGGTCTTAGGCTATATCACT-3’ (icDNA)*(****Comment****: Difference from reference was shown in Supplementary Figure 1(a))* |
| 1st run | 5'-GAAGAAGTGTTTCAGAAGCTTCTCC-3’ | BCR |  |
| 2nd run | 5'-TGAAACTCCAGACTGTCCACAGCAT-3’ | BCR |  |
| 5'-GGCCACAAAATCATACAGTGCAACG-3’ | ABL1 | 5’-CGTTGCACTGTATGATTTTGTGGCC-3’ (icDNA) |
| Control (ABL1) | 5'-GGCTGCAAATCCAAGAAGGGGCTGT-3' | ABL1 |  |
| 2 | Bose S 1998[11] | 1st run | Article referred to Cross NCP 1996[35] | BCR | Cross NCP 1996[35]: 5’-GAGCGTGCAGAGTGGAGGGAGAACA-3’ |
| ABL1 | Cross NCP 1996[35]: 5’-GGTACCAGGAGTGTTTCTCCAGACTG-3’ 5’-CAGTCTGGAGAAACACTCCTGGTACC-3’ (icDNA) |
| 2nd run | BCR | Cross NCP 1996[35]: 5’-TTCAGAAGCTTCTCCCTGACAT-3’ |
| ABL1 | Cross NCP 1996[35]: 5’-TGTTGACTGGCGTGATGTAGTTGCTTGG-3’ 5’-CCAAGCAACTACATCACGCCAGTCAACA-3’ (icDNA) |
| Control | Article referred to Melo JV 1993[42], that did not specify using BCR or ABL1 gene as control. Sequence of ABL1 variant a was used for the review. | ABL1 | Melo JV 1993[42]:5’-TTGGAGATCTCCCTGAAG-3’5’-GGAGTGTTTCTCCAGACTGTTG-3’5’-CAACAGTCTGGAGAAACACTCC-3’ (icDNA) |
| 3 | Ravetto PF 2003[13] | 1st run | 5’-CGGGAGCAGCAGAAGAAGTC-3’ | BCR | *(****Comment****: Difference from reference was shown in Supplementary Figure 1(a))* |
| 5’-TGTGATTATAGCCTAAGACCCGGAG-3’ | ABL1 | 5’-CTCCGGGTCTTAGGCTATAATCACA-3’ (icDNA) |
| 2nd run | 5’-GTGAAACTCCAGACTGTCCACAGCA-3’ | BCR |  |
| 5’-TCCACTGGCCACAAAATCATACAGT-3’ | ABL1 | 5’-ACTGTATGATTTTGTGGCCAGTGGA-3’ (icDNA) |
| Control (β actin) NR (Sequence of probe was also reported) |
| 4 | Hsu H 2004[14] | 1st run | 5'-GAATTTCAGAAGCTTCTGTGCC-3' | BCR | *(****Comment****: Difference from reference was shown in Supplementary Figure 1(a))* *(****Comment****: Type of transcript was NR, but it was M-BCR from the BCR sequence)* |
| 5'-GTTTGGGCTTCACACCATTCC-3' | ABL1 | 5’-GGAATGGTGTGAAGCCCAAAC-3’ (icDNA) |
| 2nd run | 5'-CAGATGCTGACCAACTCGTGT-3' | BCR |  |
| 5'-TTCCCCATTGTGATTATAGCCTA-3' | ABL1 | 5’-TAGGCTATAATCACAATGGGGAA-3’ (icDNA) |
| Control (G3PD, glyceraldehyde 3-phosphate dehydrogenase) NR |
| 5 | le Coutre P 2010[15] | 1st run | 5’-TTCAGATTCTCCCTGGCATCCGT-3’ | BCR | *(****Comment****: Difference from reference was shown in Supplementary Figure 1(a))* |
| 5’-GGTACCAGGAGTGTTTCTCCAGACTG-3’ | ABL1 | 5’-CAGTCTGGAGAAACACTCCTGGTACC-3’ (icDNA) |
| 2nd run | 5’-GTCCACAGCATTCCGCTGACCATCAAT-3’ | BCR |  |
| 5’-TGTTGACTGGCGTGATGTAGTTGCTTGG-3’ | ABL1 | 5’-CCAAGCAACTACATCACGCCAGTCAACA-3’ (icDNA) |
| Control (ABL1) NR |
| 6 | Song J 2011[16] | 1st run | Article referred to Maurer J 1991[24] & Weisser M 2004[43]. But Weisser M 2004[43] did not mention the nucleotide sequence. | BCR | Maurer J 1991[24]: 2 primers were used5’-GAAGTGTTTCAGAAGCTTCTCC-3’5’-GAGCGTGCAGAGTGGAGGGAGAACATCCGG-3’ |
| ABL1 | Maurer J 1991[24]: 2 primers were used5’-TGATTATAGCCTAAGACCCGGA-3’5’-TCCGGGTCTTAGGCTATAATCA-3’ (icDNA)5’-CCATTTTTGGTTTGGGCTTCACACCATTCC-3’5’-GGAATGGTGTGAAGCCCAAACCAAAAATGG-3’ (icDNA) |
| 2nd run | BCR | Maurer J 1991[24]: 2 primers were used5’-AGGAGCTGCAGATGCTGACCAACTCG-3’ *(****Comment****: Difference from reference was shown in Supplementary Figure 1(a))*5’-GAAGAAGTGTTTCAGAAGCTTCTCC-3’ |
| ABL1 | Maurer J 1991[24]: 2 primers were used5’-ATCTCCAGTGGCCAGAAAATCATACA-3’5’-TGTATGATTTTCTGGCCACTGGAGAT-3’ (icDNA) *(****Comment****: Difference from reference was shown in Supplementary Figure 2a)* 5’-TGTGATTATAGCCTAAGACCCGGAGCTTTTC-3’5’-GAAAAGCTCCGGGTCTTAGGCTATAATCACA-3’ (icDNA) |
| Control (ABL1) | ABL1 | Maurer J 1991[24]:3 forward primers were reported in 1st run:5’-ATCTGCCTGAAGCTGGTGGGCT-3’5’-GCAGCAGCCTGGAAAAGTACTT-3’ *(****Comment:*** *sequence in variant b)*5’-CAGCGGCCAGTAGCATCTGACT-3’2 forward primers were reported in 2nd run:5’-ACTGAAGCCGCTCGTTGGAACTCCAA-3’ *(****Comment****: Difference from reference was shown in Supplementary Figure 2a)*5’-GCCTCAGGGTCTGAGTGAAGCCGCTCGTTG-3’2 reverse primers were reported in 1st & 2nd run, respectively *(****Comment:*** *same as in M-BCR 1st & 2nd run, respectively)* |
| 7 | Boquett JA 2013[18] | 1st run | 5'-TTCAGAAGCTTCTCCCTG-3ꞌ | BCR |  |
| 5’-CTCCACTGGCCACAAAAT-3' | ABL1 | 5’-ATTTTGTGGCCAGTGGAG-3’ (icDNA) |
| 2nd run | 5'-TTCAGAAGCTTCTCCCTGACATCCG-3' | BCR |  |
| 5'-CTCCACTGGCCACAAAATCATACAG-3' | ABL1 | 5’-CTGTATGATTTTGTGGCCAGTGGAG-3’ (icDNA) |
| control NR |
| 8 | Ismail SI 2014[19] | 1st run | Article referred to Cross NC 1994[34] & Nogva HK 1998[39] with minor modifications. | BCR | Cross NC 1994[34] & Nogva HK 1998[39]: 5'-ACAGaATTCGCTGACCATCAATAAG-3' *(Small case letters denote bases that were changed from the natural sequence in order to introduce restriction enzyme site.)**(****Comment****: Difference from reference was shown in Supplementary Figure 1(a))* |
| ABL1 | Cross NC 1994[34]: 5'-TGTTGACTGGCGTGATGTAGTTGCTTGG-3' 5’-CCAAGCAACTACATCACGCCAGTCAACA-3’ (icDNA) |
| 2nd run | BCR | Nogva HK 1998[39]: 5’-CTGACCATCAATAAGGAAG-3’ |
| ABL1 | Nogva HK 1998[39]: 5'-TTCACACCATTCCCC-3' 5’-GGGGAATGGTGTGAA-3’ (icDNA) |
| Control (ABL1) | ABL1 | Nogva HK 1998[39]: 5'-CTGCAAATCCAAGAAGGGGCTG-3'Nogva HK 1998[39]: *(****Comment****: Same as M-BCR 1st run)* |

NCBI, National Center for Biotechnology Information